GLP-1 Drugs Face Eye Safety Concerns: Will Fresh Scrutiny Impact India's Growing Market?

GLP-1 weight-loss drugs are facing fresh scrutiny over a rare eye condition called NAION that can cause sudden, usually painless vision loss. European regulators have flagged NAION as a very rare side effect associated with semaglutide, while studies and litigation examine a possible link. Business Today’s Neetu Chandra Sharma explains the latest developments, safety concerns and what Novo Nordisk has said about its clinical trial data. Gaurang Shah, Sr. VP, Geojit Investments, discusses the importance of regulatory oversight, good manufacturing practices and the potential impact on pharma companies. With India’s GLP-1 market expanding rapidly, safety developments remain closely watched.